220 related articles for article (PubMed ID: 27602491)
1. ERBB2 mutations associated with solid variant of high-grade invasive lobular breast carcinomas.
Deniziaut G; Tille JC; Bidard FC; Vacher S; Schnitzler A; Chemlali W; Trémoulet L; Fuhrmann L; Cottu P; Rouzier R; Bièche I; Vincent-Salomon A
Oncotarget; 2016 Nov; 7(45):73337-73346. PubMed ID: 27602491
[TBL] [Abstract][Full Text] [Related]
2. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
3. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
4. Genetic analysis of pleomorphic and florid lobular carcinoma in situ variants: frequent ERBB2/ERBB3 alterations and clonal relationship to classic lobular carcinoma in situ and invasive lobular carcinoma.
Shamir ER; Chen YY; Krings G
Mod Pathol; 2020 Jun; 33(6):1078-1091. PubMed ID: 31907376
[TBL] [Abstract][Full Text] [Related]
5. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS; Wang K; Sheehan CE; Boguniewicz AB; Otto G; Downing SR; Sun J; He J; Curran JA; Ali S; Yelensky R; Lipson D; Palmer G; Miller VA; Stephens PJ
Clin Cancer Res; 2013 May; 19(10):2668-76. PubMed ID: 23575477
[TBL] [Abstract][Full Text] [Related]
6. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
Djerroudi L; El Sabeh-Ayoun A; Benoist C; Pierron G; Masliah-Planchon J; Fuhrmann L; Kieffer Y; Carton M; Ramtohul T; Callens C; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
Mod Pathol; 2024 May; 37(5):100463. PubMed ID: 38428737
[TBL] [Abstract][Full Text] [Related]
8. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
9. Targetable alterations in invasive pleomorphic lobular carcinoma of the breast.
Riedlinger GM; Joshi S; Hirshfield KM; Barnard N; Ganesan S
Breast Cancer Res; 2021 Jan; 23(1):7. PubMed ID: 33441174
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
Uchida S; Kojima T; Sugino T
Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
[TBL] [Abstract][Full Text] [Related]
11. ERBB2 mutation frequency in lobular breast cancer with pleomorphic histology or high-risk characteristics by molecular expression profiling.
Christgen M; Bartels S; Radner M; Raap M; Rieger L; Christgen H; Gluz O; Nitz U; Harbeck N; Lehmann U; Kreipe H
Genes Chromosomes Cancer; 2019 Mar; 58(3):175-185. PubMed ID: 30520184
[TBL] [Abstract][Full Text] [Related]
12. Frequent alterations of HER2 through mutation, amplification, or overexpression in pleomorphic lobular carcinoma of the breast.
Lien HC; Chen YL; Juang YL; Jeng YM
Breast Cancer Res Treat; 2015 Apr; 150(2):447-55. PubMed ID: 25773929
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
Bergeron A; MacGrogan G; Bertaut A; Ladoire S; Arveux P; Desmoulins I; Bonnefoi H; Loustalot C; Auriol S; Beltjens F; Degrolard-Courcet E; Charon-Barra C; Richard C; Boidot R; Arnould L
Mod Pathol; 2021 Jul; 34(7):1282-1296. PubMed ID: 33753865
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
15. Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
Cao L; Basudan A; Sikora MJ; Bahreini A; Tasdemir N; Levine KM; Jankowitz RC; McAuliffe PF; Dabbs D; Haupt S; Haupt Y; Lucas PC; Lee AV; Oesterreich S; Atkinson JM
Cancer Lett; 2019 Oct; 461():21-30. PubMed ID: 31229512
[TBL] [Abstract][Full Text] [Related]
16. Invasive Pleomorphic Lobular Histology Is an Adverse Prognostic Factor on Survival in Patients with Breast Cancer.
Sahin S; Karatas F; Erdem GU; Hacioglu B; Altundag K
Am Surg; 2017 Apr; 83(4):359-364. PubMed ID: 28424130
[TBL] [Abstract][Full Text] [Related]
17. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
18. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
Forster-Sack M; Zoche M; Pestalozzi B; Witzel I; Schwarz EI; Herzig JJ; Fansa H; Tausch C; Ross J; Moch H; Varga Z
J Pathol Clin Res; 2024 Mar; 10(2):e12362. PubMed ID: 38335502
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Shah V; Nowinski S; Levi D; Shinomiya I; Kebaier Ep Chaabouni N; Gillett C; Grigoriadis A; Graham TA; Roylance R; Simpson MA; Pinder SE; Sawyer EJ
Breast Cancer Res; 2017 Jan; 19(1):7. PubMed ID: 28095868
[TBL] [Abstract][Full Text] [Related]
20. Targeted capture massively parallel sequencing analysis of LCIS and invasive lobular cancer: Repertoire of somatic genetic alterations and clonal relationships.
Sakr RA; Schizas M; Carniello JV; Ng CK; Piscuoglio S; Giri D; Andrade VP; De Brot M; Lim RS; Towers R; Weigelt B; Reis-Filho JS; King TA
Mol Oncol; 2016 Feb; 10(2):360-70. PubMed ID: 26643573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]